Fate Therapeutics, Inc. (FATE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.48+2.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Revenue stabilizes or grows: FY27 rev -15.6% vs 0% target.
Fate Therapeutics is developing new cell therapies for cancer and immune diseases. The company has recently beaten earnings estimates twice. It is working to extend its cash runway through restructuring. The stock has gained 154% in the past 63 days, showing strong investor interest.
Fate is still loss-making with negative free cash flow. Analysts expect revenue to decline about 12% next year. There are concerns about cash management and recent leadership changes. Litigation and restructuring risks remain significant.
The market expects about -12% revenue growth next year and a continued loss-making profile. Our fair value is near $0.79, reflecting these challenges. The stock price is up sharply, implying optimism that may not match fundamentals.
Breaks if: Cash runway falls below 12 months
Breaks if: Additional key executive departures occur
Breaks if: YoY revenue growth falls below -12% in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state reflects a watchful approach, as the company is loss-making but has potential due to its clinical advancements.
The market appears to have a low expectations gap, indicating that some cautious optimism is already factored in. Valuation shows a premium compared to peers, suggesting that investors may be pricing in the optionality of future successes.
Management is focused on advancing clinical trials and maintaining an operating runway, but recent financial performance has been neutral. The company has shown mixed results in its clinical development efforts, which could influence future performance.
Key factors for FATE include the outcomes of upcoming clinical trials and guidance updates. Additionally, broader sector performance, particularly from leading healthcare companies, could impact sentiment and momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. The company is advancing FT819 clinical development for autoimmune diseases. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, FATE's prospects will depend on its ability to execute on clinical trials and manage financial stability amid sector dynamics. Not investment advice.